Last updated 2026-07-20
- Went public on Hamburg Stock Exchange (T9G), Mar 2023
- Raised $21.6M convertible note led by GEM Global Yield LLC SCS, Apr 2021
- Raised $9M Series A led by Israel Biotech Fund, Jun 2016
Total raised
$31.2M
Last: Undisclosed Round 2024-11
Stage
Public
Founded
2012
Headcount
7
HQ
London, United Kingdom
Sector
Health Tech & Life Sciences
About
Vidac Pharma is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class medicines for oncologic and onco-dermatologic diseases. The company's research targets abnormal metabolic processes that characterize cancer cells, aiming to restore normal cellular regulation and inhibit tumor progression. Vidac's scientific platform targets the Warburg effect, and its pipeline includes VDA-1102 for actinic keratosis and cutaneous T-cell lymphoma, and VDA-1275 for solid tumors.
Funding history · 5 rounds · $31.2M total
2026-03
Secondary
Undisclosed
★ directors★ Certain shareholders★ directors of the company★ Directors of Vidac Pharma Holding PLC★ Main Shareholders of Vidac Pharma Holding PLC★ Certain shareholders and directors of the Company
2024-11
Secondary
$648K
2023-02
Follow-on PO
Undisclosed
2021-04
Convertible Debt
$21.6M
★ GEM Global Yield LLC SCS
2016-06
A Round
$9.0M
★ Israel Biotech FundEd SaltzmanRobert SpiegelMivtach Shamir Holdings
Headcount over time
From 6 (2016-06) to 8 (2025-12) · +2 (+33%) · 18 points · source: Finder history + radar grounding
Q&A
- What is Vidac Pharma's primary focus?
- Vidac Pharma is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for oncologic and dermatologic diseases, specifically targeting the VDAC/HK2 system in malignant cells.
- What is the status of Vidac Pharma's lead drug, VDA-1102?
- Vidac Pharma's lead drug, VDA-1102, has successfully completed a Phase 2b clinical trial in actinic keratosis (AK) and is currently in a Phase 2a clinical trial in Cutaneous T-Cell Lymphoma (CTCL) in Israel.
- When did Vidac Pharma go public and on which exchange?
- Vidac Pharma went public in March 2023 on the Hamburg Stock Exchange with a valuation of $60,000,000.
- What is Vidac Pharma's employee count?
- Vidac Pharma has 1-10 employees.
- What is the latest development regarding Vidac Pharma's VDA-1275 cancer drug candidate?
- In March 2024, Vidac Pharma received a Japanese Patent Office Notice of Allowance for its VDA-1275 cancer drug candidate.
- What recent patent was granted to Vidac Pharma in the U.S.?
- In September 2024, the U.S. granted Vidac Pharma a patent offering broad protection of the mode of action underlying its oncology drug candidates.
- What were the results of Vidac Pharma's VDA-1102 interim Phase 2a data for CTCL?
- In January 2024, Vidac Pharma reported positive interim Phase 2a data for its lead asset VDA-1102 in the orphan disease cutaneous T-cell lymphoma (CTCL).
- What is Vidac Pharma's total funding raised to date?
- Vidac Pharma has raised a total of $9,645,651 across its funding rounds.
Team · 1
Max Herzberg
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pharma-companiesoncologyoral-drugstargeted-therapydrug-discoverybiotechnologydermatologydrug-developmenttopical-treatmentcancerbiopharmaceutical
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | vidacpharma.com |
|---|---|
| linkedin.com/company/3121139 |
Identifiers & details
| Founded | 2012 |
|---|---|
| Employees (exact) | 7 |
| Offices | Brookline |
| Status reason | Public on Hamburg Stock Exchange on Mar, 2023 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Public Offering | 2023-03 | Hamburg Stock Exchange | T9G |
Radar intelligence
Patents
| EPO | 6 |
|---|
Web history (Wayback)
| Domain | vidacpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514717651 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2012-01-16 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 1 |
| Registry events | 1 — charge (1) |
| Registered address | אופנהיימר 7 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-10-19 | רישום שעבוד |